Skip to main content

Table 1 Follow-up antiphospholipid antibody (aPL) results in 57 patients with at least one high- or low-risk aPL profile

From: The clinical relevance of different antiphospholipid antibody profiles in pediatric rheumatology patients

 

Initial LA + and/or aCL/aβ2GPI ≥ 40U

Initial LA- and aCL/aβ2GPI 20-39U

(n:34)

(n:23)

Mean Follow up (+/- SD) (y)

4.4 ± 5.0

3.2 ± 2.9

Subsequent aPL positive / # of patients with repeat aPL

25/27 (93%)

7/15 (47%)

• Repeat LA positive / Initial LA positive

18/27 (67%)

2/0#

• Repeat aCL/aβ2GPI positive / Initial aCL/aβ2GPI positive

19/23 (83%)

5/15 (36%)*

  1. LA: lupus anticoagulant; aCL: anticardiolipin antibody; and aβ2GPI: anti-β2 glycoprotein-I antibody. 93% (25) of patients in the high-risk profile group continued to have positive results on repeat testing, with 18 (67%) of 27 initial LA positive patients remaining LA positive, and 19 (83%) of 23 initial aCL and/or aβ2GPI positive patients remaining positive for aCL and/or aβ2GPI. On the other hand, 47% (7) of patients in the low-risk group continued to have positive results on repeat testing, 5 (36%) of which continued with positive aCL and/or aβ2GPI. #Two patients who initially only had low-titer positive aCL (one with IgM and one with IgG), later developed positive LA. *Two patients had subsequent high-risk aPL titers with aCL ≥ 40U
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096